Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9007919 | 1.00 | TAAR1 (0.48) | TAAR1TSHRNPC1PTGS1PTGS2 | |
| SCHEMBL23014880 | 1.00 | TAAR1 (0.48) | TAAR1TSHRNPC1PTGS1PTGS2 | |
| SCHEMBL23014743 | 0.88 | TAAR1 (0.47) | TAAR1TSHRNPC1PTGS1PTGS2 | |
| SCHEMBL23015149 | 0.88 | TAAR1 (0.47) | TAAR1TSHRNPC1PTGS1PTGS2 | |
| SCHEMBL7116263 | 0.81 | TAAR1 (0.70) | TAAR1TSHRNPC1PTGS1PTGS2 | |
| SCHEMBL8571535 | 0.81 | TAAR1 (0.70) | TAAR1TSHRNPC1PTGS1PTGS2 | |
| SCHEMBL6734915 | 0.81 | TAAR1 (0.70) | TAAR1TSHRNPC1PTGS1PTGS2 | |
| SCHEMBL271561 | 0.80 | TAAR1 (0.57) | TAAR1TSHRNPC1PTGS1PTGS2 | |
| SCHEMBL271466 | 0.80 | TAAR1 (0.57) | TAAR1TSHRNPC1PTGS1PTGS2 | |
| SCHEMBL270626 | 0.80 | TAAR1 (0.57) | TAAR1TSHRNPC1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | claimed |
| EP-4017499-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | Emory University (US) | 2022-06-29 | — | — | EP | claimed |
| WO-2021035214-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2021-02-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | TAAR1 4098/4885TSHR 4673/4885NPC1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.